Solid Biosciences to Participate at the Piper Sandler 34th Annual Healthcare Conference
Rhea-AI Summary
Solid Biosciences Inc. (SLDB) announced participation in the Piper Sandler 34th Annual Healthcare Conference on December 1, 2022, at 10:30 a.m. ET. CEO Ilan Ganot, AavantiBio CEO Bo Cumbo, and CSO Carl Morris will partake in a fireside chat. A live webcast will be accessible on the company's investor relations website with a replay available post-event. Solid Biosciences is dedicated to developing therapies for Duchenne muscular dystrophy and is working on a gene therapy candidate, SGT-003, aimed at addressing the underlying mutation of the disease.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, SLDB declined NaN%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
CAMBRIDGE, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Ilan Ganot, Chief Executive Officer, President and Co-Founder of Solid, Bo Cumbo, President and Chief Executive Officer of AavantiBio, and Carl Morris, PhD, Chief Scientific Officer of Solid, will participate in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference on Thursday, December 1, 2022, at 10:30 a.m. ET.
A live webcast will be available on the Company’s investor relations website, under the Events page accessible here: https://investors.solidbio.com/news-and-events/events. A replay will be available on the Company's website following the event.
About Solid Biosciences
Solid Biosciences is a life sciences company focused on advancing transformative treatments to improve the lives of patients living with Duchenne. Disease-focused and founded by a family directly impacted by Duchenne, our mandate is simple yet comprehensive – work to address the disease at its core by correcting the underlying mutation that causes Duchenne with our gene therapy candidate SGT-003. For more information, please visit www.solidbio.com.
Investor Contact:
David Carey
FINN Partners
212-867-1768
David.Carey@finnpartners.com
Media Contact:
Erich Sandoval
FINN Partners
917-497-2867
Erich.Sandoval@finnpartners.com
FAQ
When will Solid Biosciences participate in the Piper Sandler Healthcare Conference?
Who will represent Solid Biosciences at the conference?
Where can I watch the Solid Biosciences conference webcast?
What is SGT-003 being developed by Solid Biosciences?
What is the focus of Solid Biosciences?
